Related references
Note: Only part of the references are listed.Complement deposition at the neuromuscular junction in seronegative myasthenia gravis
Sarah Hoffmann et al.
ACTA NEUROPATHOLOGICA (2020)
Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial
James F. Howard et al.
JAMA NEUROLOGY (2020)
Antagonism of the Neonatal Fc Receptor as an Emerging Treatment for Myasthenia Gravis
Karissa L. Gable et al.
FRONTIERS IN IMMUNOLOGY (2020)
New Approaches to Targeting B Cells for Myasthenia Gravis Therapy
Ruksana Huda
FRONTIERS IN IMMUNOLOGY (2020)
'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab
John Vissing et al.
JOURNAL OF NEUROLOGY (2020)
Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis
Susanna Brauner et al.
JAMA NEUROLOGY (2020)
Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab
Kioa Lente Wijnsma et al.
CLINICAL PHARMACOKINETICS (2019)
Therapies Directed Against B-Cells and Downstream Effectors in Generalized Autoimmune Myasthenia Gravis: Current Status
Grayson Beecher et al.
DRUGS (2019)
Long-term safety and efficacy of eculizumab in generalized myasthenia gravis
Srikanth Muppidi et al.
MUSCLE & NERVE (2019)
Bortezomib in antibody-mediated autoimmune diseases (TAVAB): study protocol for a unicentric, non-randomised, non-placebo controlled trial
Siegfried Kohler et al.
BMJ OPEN (2019)
Review of the Current Knowledge on the Role of Stem Cell Transplantation in Neurorehabilitation
Anna M. Kamelska-Sadowska et al.
BIOMED RESEARCH INTERNATIONAL (2019)
Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis
James F. Howard et al.
NEUROLOGY (2019)
Efgartigimod A novel antibody depletion therapy in myasthenia gravis
Amanda C. Guidon et al.
NEUROLOGY (2019)
Myasthenia gravis
Nils Erik Gilhus et al.
NATURE REVIEWS DISEASE PRIMERS (2019)
Complement Therapeutics in Autoimmune Disease
Joshua M. Thurman et al.
FRONTIERS IN IMMUNOLOGY (2019)
Refractory myasthenia gravis successfully treated with ofatumumab
Michael J. Waters et al.
MUSCLE & NERVE (2019)
Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study
Austin G. Kulasekararaj et al.
BLOOD (2019)
M281, an Anti-FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First-in-Human Study
Leona E. Ling et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
Immunotherapy Deriving from CAR-T Cell Treatment in Autoimmune Diseases
Yuehong Chen et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2019)
Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria
Robert M. Stern et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2019)
Autologous haematopoietic stem cell transplantation for neurological diseases
Joachim Burman et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2018)
B CELLS IN THE PATHOPHYSIOLOGY OF MYASTHENIA GRAVIS
John S. Yi et al.
MUSCLE & NERVE (2018)
CAR T-cell Therapy: A New Era in Cancer Immunotherapy
Miliotou N. Androulla et al.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2018)
Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event
Joseph R. Berger et al.
JOURNAL OF NEUROVIROLOGY (2018)
Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis
Karen Hewett et al.
NEUROLOGY (2018)
Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action
Douglas Sheridan et al.
PLOS ONE (2018)
Targeting B Cells and Plasma Cells in Autoimmune Diseases
Katharina Hofmann et al.
FRONTIERS IN IMMUNOLOGY (2018)
Adverse Effects of Immunoglobulin Therapy
Yi Guo et al.
FRONTIERS IN IMMUNOLOGY (2018)
Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans
Peter Ulrichts et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
The Use of Human Mesenchymal Stem Cells as Therapeutic Agents for the in vivo Treatment of Immune-Related Diseases: A Systematic Review
Alessander Leyendecker et al.
FRONTIERS IN IMMUNOLOGY (2018)
Autologous Hematopoietic Stem Cell Transplantation for Autoimmune Diseases: From Mechanistic Insights to Biomarkers
Kelen Cristina Ribeiro Malmegrim et al.
FRONTIERS IN IMMUNOLOGY (2018)
Myasthenia gravis: the role of complement at the neuromuscular junction
James F. Howard
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES (2018)
ONX-0914, a selective inhibitor of immunoproteasome, ameliorates experimental autoimmune myasthenia gravis by modulating humoral response
Ru-Tao Liu et al.
JOURNAL OF NEUROIMMUNOLOGY (2017)
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study
James F. Howard et al.
LANCET NEUROLOGY (2017)
RITUXIMAB TREATMENT OF MYASTHENIA GRAVIS: A SYSTEMATIC REVIEW
Rup Tandan et al.
MUSCLE & NERVE (2017)
Rituximab as treatment for anti-MuSK myasthenia gravis Multicenter blinded prospective review
Michael K. Hehir et al.
NEUROLOGY (2017)
Subcutaneous immunoglobulin in myasthenia gravis exacerbation A prospective, open-label trial
Grayson Beecher et al.
NEUROLOGY (2017)
Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab
Dagur Ingi Jonsson et al.
NEUROMUSCULAR DISORDERS (2017)
The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study
Peter Kiessling et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience
Christiane Schneider-Gold et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2017)
Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment
Fanny Huynh Du et al.
AUTOIMMUNITY HIGHLIGHTS (2017)
B-CELL-ACTIVATING FACTOR IS ELEVATED IN SERUM OF PATIENTS WITH MYASTHENIA GRAVIS
Sa-Yoon Kang et al.
MUSCLE & NERVE (2016)
International consensus guidance for management of myasthenia gravis: Executive summary
Donald B. Sanders et al.
NEUROLOGY (2016)
Treatment for Refractory Myasthenia Gravis-New Lymphs for Old
Daniel B. Drachman
JAMA NEUROLOGY (2016)
Myasthenia Gravis Treated With Autologous Hematopoietic Stem Cell Transplantation
Adam Bryant et al.
JAMA NEUROLOGY (2016)
Toxicity and management in CAR T-cell therapy
Challice L. Bonifant et al.
MOLECULAR THERAPY-ONCOLYTICS (2016)
Subcutaneous Immunoglobulin Therapy in the Chronic Management of Myasthenia Gravis: A Retrospective Cohort Study
P. R. Bourque et al.
PLOS ONE (2016)
Future perspectives in target-specific immunotherapies of myasthenia gravis
Marinos C. Dalakas
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2015)
Targeting the Fc receptor in autoimmune disease
Xinrui Li et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2014)
Intravenous immunoglobulin as treatment for myasthenia gravis: current evidence and outcomes
Majed Alabdali et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2014)
Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma
Lenka Kubiczkova et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2014)
Targeting complement system to treat myasthenia gravis
Ruksana Huda et al.
REVIEWS IN THE NEUROSCIENCES (2014)
IgG subclasses and allotypes: from structure to effector functions
Gestur Vidarsson et al.
FRONTIERS IN IMMUNOLOGY (2014)
Disturbed B cell subpopulations and increased plasma cells in myasthenia gravis patients
Siegfried Kohler et al.
JOURNAL OF NEUROIMMUNOLOGY (2013)
The thymus in autoimmune Myasthenia Gravis: Paradigm for a tertiary lymphoid organ
J. -M. Weiss et al.
REVUE NEUROLOGIQUE (2013)
New treatments for myasthenia: a focus on antisense oligonucleotides
Corrado Angelini et al.
Drug Design Development and Therapy (2013)
Functional defect in regulatory T cells in myasthenia gravis
Muthusamy Thiruppathi et al.
MYASTHENIA GRAVIS AND RELATED DISORDERS I (2012)
Molecular Mimicry as a Mechanism of Autoimmune Disease
Matthew F. Cusick et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2012)
Muscle autoantibodies in myasthenia gravis: beyond diagnosis?
Matthew N. Meriggioli et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2012)
CD19 as an attractive target for antibody-based therapy
Ohad Hammer
MABS (2012)
Belimumab Is Approved by the FDA: What More Do We Need to Know to Optimize Decision Making?
Diane Lewis Horowitz et al.
CURRENT RHEUMATOLOGY REPORTS (2012)
Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases
Lisa Kobrynski
BIOLOGICS-TARGETS & THERAPY (2012)
Intravenous immunoglobulin for myasthenia gravis
Philippe Gajdos et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2012)
Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis
Revital Aricha et al.
JOURNAL OF AUTOIMMUNITY (2011)
Complement and cytokine based therapeutic strategies in myasthenia gravis
Erdem Tuezuen et al.
JOURNAL OF AUTOIMMUNITY (2011)
B-Cell-Activating Factor and Autoimmune Myasthenia Gravis
Samia Ragheb et al.
AUTOIMMUNE DISEASES (2011)
Stem cell transplantation for autoimmune diseases
Thomas Huegle et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
The development and function of regulatory T cells
Creg J. Workman et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2009)
Current Proposed Mechanisms of Action of Intravenous Immunoglobulins in Inflammatory Neuropathies
Saiju Jacob et al.
CURRENT NEUROPHARMACOLOGY (2009)
CORRELATION OF C3 LEVEL WITH SEVERITY OF GENERALIZED MYASTHENIA GRAVIS
Aidong Liu et al.
MUSCLE & NERVE (2009)
Classical complement pathway in experimental autoimmune myasthenia gravis pathogenesis
Premkumar Christadoss et al.
MYASTHENIA GRAVIS AND RELATED DISORDERS: 11TH INTERNATIONAL CONFERENCE (2008)
Antisense treatment for myasthenia gravis - Experience with Monarsen
Jon D. Sussman et al.
MYASTHENIA GRAVIS AND RELATED DISORDERS: 11TH INTERNATIONAL CONFERENCE (2008)
Advances in the understanding of the mechanism of action of IVIg
Hans-Peter Hartung
JOURNAL OF NEUROLOGY (2008)
Plasma cell development: From B-cell subsets to long-term survival niches
Kirsten A. Fairfax et al.
SEMINARS IN IMMUNOLOGY (2008)
Steroids and immunosuppressant drugs in myasthenia gravis
Sivakumar Sathasivam
NATURE CLINICAL PRACTICE NEUROLOGY (2008)
Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockade
Liming Liu et al.
JOURNAL OF IMMUNOLOGY (2007)
IV immunoglobulin in patients with myasthenia gravis - A randomized controlled trial
Lorne Zinman et al.
NEUROLOGY (2007)
IL-1 receptor antagonist-mediated therapeutic effect in murine myasthenia gravis is associated with suppressed serum proinflammatory cytokines, C3, and anti-acetylcholine receptor IgG1
H Yang et al.
JOURNAL OF IMMUNOLOGY (2005)
Hematopoietic stem cell transplantation for multiple sclerosis
RK Burt et al.
ARCHIVES OF NEUROLOGY (2005)
The role of the complement system in innate immunity
H Rus et al.
IMMUNOLOGIC RESEARCH (2005)
Response of thymectomy:: clinical and pathological characteristics among seronegative and seropositive myasthenia gravis patients
GR Guillermo et al.
ACTA NEUROLOGICA SCANDINAVICA (2004)
The immunologic role of thymectomy in the treatment of myasthenia gravis: Implication of thymus-associated B-lymphocyte subset in reduction of the anti-acetylcholine receptor antibody titer
M Okumura et al.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2003)
Share Paper
